Core Viewpoint - Zhongsheng Pharmaceutical (002317.SZ) reported a decline in revenue for the first half of 2025, while net profit saw significant growth, indicating a mixed performance in financial results [1] Financial Performance - The company achieved operating revenue of 1.3 billion yuan, a year-on-year decrease of 4.74% [1] - The net profit attributable to shareholders of the listed company was 188 million yuan, reflecting a year-on-year increase of 114.96% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 187 million yuan, showing a year-on-year growth of 7.42% [1] - Basic earnings per share were reported at 0.22 yuan [1]

Group 1 - The core viewpoint of the article is that Zhongsheng Pharmaceutical (002317.SZ) reported a decline in revenue but a significant increase in net profit for the first half of the year [1] Group 2 - The company's operating revenue for the first half of the year was 1.3 billion yuan, representing a year-on-year decrease of 4.74% [1] - The net profit attributable to shareholders of the listed company was 188 million yuan, showing a year-on-year increase of 114.96% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 187 million yuan, reflecting a year-on-year growth of 7.42% [1]

Group 1 - The core viewpoint of the articles highlights the strong performance of Zhongsheng Pharmaceutical in the first half of 2025, with a significant increase in revenue and net profit, indicating a successful turnaround from previous losses [1] - The company reported a revenue of 1.3 billion yuan and a net profit of 188 million yuan, marking a year-on-year growth of 114.96% [1] - The company is focusing on a mid-term strategic plan centered on traditional Chinese medicine, innovation, and a diversified sales approach to enhance competitiveness [1] Group 2 - The launch of the innovative flu drug, Anladiwei tablets, is a major breakthrough for the company, expected to capture a significant share of the flu medication market [2] - Anladiwei tablets are characterized by rapid efficacy and low resistance, showing strong inhibition against various flu virus strains [2] - The company has established a partnership with Kexing Pharmaceutical to accelerate the commercialization of Anladiwei tablets, which have also obtained medical insurance negotiation qualifications [2] Group 3 - In the respiratory pipeline, the company has successfully launched two products and is advancing the clinical trials for a pediatric version of Anladiwei [3] - The company is also developing ZSP0540, an innovative drug targeting respiratory syncytial virus (RSV), which has shown strong antiviral activity and is currently in preclinical research [3] - ZSP0540 is expected to meet clinical needs as there are currently no specific treatments for RSV in the domestic market [3] Group 4 - In the metabolic disease research pipeline, RAY1225 injection is one of the few weight loss and blood sugar-lowering drugs in III phase clinical trials, showing promising results [4] - The unique design of RAY1225 aims to minimize side effects and improve patient compliance, making it attractive to multinational pharmaceutical companies [4] - The company is also developing ZSP1601 tablets for treating metabolic dysfunction-related fatty liver disease, which is a significant domestic innovation project [4]

Group 1 - The monkeypox concept sector declined by 0.91%, ranking among the top declines in concept sectors, with leading decliners including Aladdin, Tsinghua Tongfang, and Hongyuan Pharmaceutical [1] - Among the 61 stocks in the monkeypox concept sector, 17 stocks saw price increases, with Kangchen Pharmaceutical, Botao Bio, and Yipin Hong leading the gains at 3.17%, 2.18%, and 1.82% respectively [1] - The monkeypox concept sector experienced a net outflow of 1.397 billion yuan from main funds today, with Han Yu Pharmaceutical seeing the largest outflow of 339 million yuan [2][3] Group 2 - The top gainers in the monkeypox concept sector included Kangchen Pharmaceutical, Jihigh Development, and Lepu Medical, with net inflows of 27.1 million yuan, 17.6 million yuan, and 12.5 million yuan respectively [4] - The stocks with the largest net outflows in the monkeypox concept sector included Han Yu Pharmaceutical, Zhongsheng Pharmaceutical, and Weixin Bio, with outflows of 339 million yuan, 114 million yuan, and 99.5 million yuan respectively [2][3] - The overall performance of the monkeypox concept sector reflects a challenging market environment, with significant capital outflows impacting stock prices [2][4]

证券代码：002317 公告编号：2025-093 广东众生药业股份有限公司 2025 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于同意广东众生药业股份有限公司向特定 对象发行股票注册的批复》（证监许可〔2023〕891 号）同意，广东众生药业股 份有限公司（以下简称"公司"）向 12 名特定对象发行人民币普通股（A 股） 38,969,401 股，发行价格为 15.36 元/股，实际募集资金总额为 598,569,999.36 元，扣除各项发行费用 8,373,028.97 元（不含税）后，募集资金净额为 590,196,970.39 元，本次发行募集资金已于 2023 年 6 月 15 日全部汇入公司指定 存储账户，并由众华会计师事务所（特殊普通合伙）进行了验证，于 2023 年 6 月 16 日出具《验资报告》（众会字（2023）第 07869 号）。 （二）以前年度已使用金额、本报告期使用金额及当前余额 截至 2025 ...

广东众生药业股份有限公司 2025 年半年度财务报告 广东众生药业股份有限公司 2025 年半年度财务报告 （本报告未经审计） 2025 年 08 月 1 广东众生药业股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：广东众生药业股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 991,600,942.78 | 1,399,449,534.39 | | 结算备付金 | 0.00 | 0.00 | | 拆出资金 | 0.00 | 0.00 | | 交易性金融资产 | 174,950,452.55 | 305,990,071.36 | | 衍生金融资产 | 0.00 | 0.00 | | 应收票据 | 644,596,643.34 | 466,394,068.02 | | 应收账款 | 628,057,996.82 | 533,207,49 ...

2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 证券代码：002317 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 总计 | - | - | - | | | | | | | - | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 其他关联资金往来 | 资金往 来方名 | 往来方与上 市公司的关 | 上市公司核 | 2025 年期 | 2025 年半年 度往来累计 | 2025 年半年 度往来资金 | 2025 年半年 | 2025 | 年半年 往来形 | 往来性质 （经营性往 | | | | | 算的会计科 | 初往来资 | | | 度偿还累计 | 度期末往来 | | | | | | | | | 发生金额（不 | 的利息（如 | | | 成原因 | 来、非经营性 | | | 称 | 联关系 | 目 | 金余额 | | | 发生金额 | 资金余额 | | | | | | | | | 含利息） | 有） | | | | 往来） | | 控股股东、实际控制 人及其附属企业 | 无 | ...

证券代码：002317 公告编号：2025-091 广东众生药业股份有限公司 第八届监事会第二十六次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）第八届监事会第二十六次 会议的会议通知于 2025 年 8 月 15 日以专人形式送达全体监事，会议于 2025 年 8 月 27 日在公司会议室以现场和通讯表决方式召开。本次会议应出席监事 3 人， 实际出席监事 3 人，会议由公司监事会主席谭珍友先生主持，董事会秘书列席本 次会议。本次会议的召集和召开符合法律、法规和《公司章程》的有关规定。经 与会监事认真审议，以记名投票方式表决，做出如下决议： 证券代码：002317 公告编号：2025-091 经审核，监事会认为董事会编制和审议公司 2025 年半年度报告的程序符合 法律、行政法规及中国证监会的规定，报告内容真实、准确、完整地反映了上市 公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：3 票同意，0 票反对，0 票弃权。 二、审议通过了《2025 年半年度募集资金存放与使用情况 ...

每经AI快讯，众生药业（SZ 002317，收盘价：21.29元）8月28日晚间发布公告称，公司第八届第二十 六次董事会会议于2025年8月27日在公司会议室以现场和通讯表决方式召开。会议审议了《公司2025年 半年度报告及摘要》等文件。 2024年1至12月份，众生药业的营业收入构成为：医药制造占比94.93%，医药贸易占比4.13%，其他业 务占比0.95%。 截至发稿，众生药业市值为181亿元。 （记者 张喜威） 每经头条（nbdtoutiao）——申请超2万份，已开出41家，加盟海底捞，你要准备多少钱？1000万元不算 多，真实"账单"公布 ...

证券代码：002317 公告编号：2025-090 广东众生药业股份有限公司 第八届董事会第二十六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）第八届董事会第二十六次 会议的会议通知于 2025 年 8 月 15 日以专人形式送达全体董事，会议于 2025 年 8 月 27 日在公司会议室以现场和通讯表决方式召开。本次会议应出席董事 9 人， 实际出席董事 9 人。会议由公司董事长陈永红先生主持，全体监事、董事会秘书 列席会议。本次会议的召集和召开符合法律、法规和《公司章程》的有关规定。 经与会董事认真审议，以记名投票方式表决，做出如下决议： 一、审议通过了《公司 2025 年半年度报告及摘要》。 表决结果：9 票同意，0 票反对，0 票弃权。 备注：具体内容详见信息披露媒体：《证券时报》《上海证券报》和巨潮资讯 网 （www.cninfo.com.cn）。 第 1页 共 2页 证券代码：002317 公告编号：2025-090 广东众生药业股份有限公司董事会 二〇二五年八月二十七日 第 2页 共 ...